|
|
|
TACT2 Clinical Trial Receives Funding!
TACT2, will focus on the benefits of removing toxic metal pollutants in patients with diabetes who have had a prior heart attack.
TACT2 is a follow-up on the positive results of TACT (Trial to Assess Chelation Therapy), the largest study ever conducted on chelation therapy, published in 2013.
Dr. Gannage's clinic has conducted EDTA chelation therapy since 1999. In 2007, Dr. Gannage enrolled the first TACT participant in Canada, saving the trial from cancelled funding and extinction. The randomized, placebo-controlled trial, sponsored by the NIH, demonstrated that EDTA chelation therapy offers a significant reduction in cardiovascular events in patients over 50 who have had a previous heart attack. Patients with diabetes in particular demonstrated a marked reduction in cardiovascular events. TACT also showed that chelation treatments are exceedingly safe.
Click here for more information on TACT and TACT2.
|
|
|
|
|
|
|
|